Supernus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson?s disease (PD). The resubmission is now considered filed, with a user fee goal date (PDUFA date) of April 5, 2024.